1-Methyl-3-<3-methyl-phenyl>-2-imidazolidinon | 91718-01-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 1-Methyl-3-<3-methyl-phenyl>-2-imidazolidinon
• 英文别名: 1-methyl-3-m-tolyl-imidazolidin-2-one；1-Methyl-3-(3-methylphenyl)imidazolidin-2-one
• CAS: 91718-01-3
• 化学式: C₁₁H₁₄N₂O
• 分子量: 190.245
• InChiKey: LPMJCJNESMISAE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES
  申请人：HOENKE Christoph

  公开号：US20100197656A1

  公开（公告）日：2010-08-05

  Dihydrothienopyrimidines of formula 1 and the pharmacologically acceptable salts, enantiomers, racemates, hydrates, or solvates thereof, which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.

  公式1中的二氢噻唑嘧啶及其药理学上可接受的盐、对映体、消旋体、水合物或溶剂化物，适用于治疗呼吸或胃肠疾病、关节、皮肤或眼睛的炎症性疾病、外周或中枢神经系统疾病或癌症，以及含有这些化合物的制药组合物。
• SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS
  申请人：Karos Pharmaceuticals, Inc.

  公开号：US20150080393A1

  公开（公告）日：2015-03-19

  The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

  本发明涉及螺环化合物，它们是色氨酸羟化酶（TPH）的抑制剂，特别是isoform 1（TPH1），可用于治疗与外周血清素相关的疾病或疾病，例如胃肠道、心血管、肺部、炎症、代谢和低骨量疾病，以及血清素综合症和癌症。
• Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease
  申请人：Lycera Corporation

  公开号：US10556898B2

  公开（公告）日：2020-02-11

  The invention provides indazolyl thiadiazolamines and related compounds, pharmaceutical compositions, methods of inhibiting Rho-associated protein kinase, and methods of treating inflammatory disorders, immune disorders, fibrotic disorders, and other medical disorders using such compounds. An exemplary indazolyl thiadiazolamine compound is an N-(3-(5-((1H-indazol-5-yl)amino)-1,2,4-thiadiazol-3-yl)phenyl)-heteroaryl-carboxamide compound.

  本发明提供了吲唑基噻二唑胺和相关化合物、药物组合物、抑制Rho相关蛋白激酶的方法，以及使用此类化合物治疗炎症性疾病、免疫性疾病、纤维化疾病和其他疾病的方法。一种示例性的吲唑基噻二唑胺化合物是N-(3-(5-((1H-吲唑-5-基)氨基)-1,2,4-噻二唑-3-基)苯基)-杂芳基甲酰胺化合物。
• INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE
  申请人：Lycera Corporation

  公开号：US20190276447A1

  公开（公告）日：2019-09-12

  The invention provides indazolyl thiadiazolamines and related compounds, pharmaceutical compositions, methods of inhibiting Rho-associated protein kinase, and methods of treating inflammatory disorders, immune disorders, fibrotic disorders, and other medical disorders using such compounds. An exemplary indazolyl thiadiazolamine compound is an N-(3-(5-((1H-indazol-5-yl)amino)-1,2,4-thiadiazol-3-yl)phenyl)-heteroaryl-carboxamide compound.
• US7723341B2
  申请人：——

  公开号：US7723341B2

  公开（公告）日：2010-05-25